South San Francisco, Calif. — December 16, 2025 — Leads & Copy — Sutro Biopharma, Inc. (NASDAQ: STRO) announced on December 15, 2025, that its Compensation Committee granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees.
The grants were an inducement for the employees’ acceptance of employment with Sutro. The Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options and RSUs are subject to the terms and conditions of Sutro’s Amended and Restated 2021 Equity Inducement Plan. One-fourth of the shares underlying the stock options will vest on the one-year anniversary of the employee’s hire date and monthly thereafter until fully vested on the fourth anniversary, contingent upon the employee’s continued service with Sutro.
Similarly, one-fourth of the shares subject to the RSUs will vest on the one-year anniversary of the employee’s hire date and annually thereafter until fully vested on the fourth anniversary, also subject to the employee’s continued service with Sutro.
Sutro Biopharma, Inc. is focused on advancing a next-generation antibody-drug conjugate (ADC) platform. This platform is designed to deliver single- and dual-payload ADCs, which the company believes will provide meaningful breakthroughs for patients with cancer. By optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types.
With capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine cancer therapy. The company’s pipeline of single- and dual-payload ADCs targets oncology markets with limited treatment options and a need for improved therapies.
Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
Source: Sutro Biopharma
